Becton Dickinson
| BD (Becton, Dickinson and Company) | |
|---|---|
| legal form | Corporation |
| ISIN | US0758871091 |
| founding | 1897 |
| Seat | Franklin Lakes , United States |
| management | Tom Poland ( Chairman and CEO ) |
| Number of employees | 65,000 (according to Annual Report 2019) |
| sales | $ 17.3 billion (Annual Report 2019) |
| Branch | Medical technology |
| Website | bd.com |
| As of June 25, 2020 | |
BD (Becton, Dickinson and Company) is one of the largest international medical technology companies that develops, produces and sells disposable medical items, device systems and reagents. BD serves hospitals, healthcare facilities, life scientists, clinical laboratories and the pharmaceutical industry.
The focus is particularly on improving medication management and patient safety, supporting infection prevention practices, providing equipment for surgical and interventional procedures, improving drug delivery, supporting anesthesiological care, improved diagnosis of infectious diseases and cancer, cell research and the Treatment of diabetes.
Founded in 1897 and headquartered in Franklin Lakes , New Jersey, the company employs more than 65,000 people and serves more than 190 countries. The company is listed on the New York Stock Exchange and in the S&P 500 Index . In the Fortune 500 list of 2019, BD was ranked 195th. In 2019, BD was included in the list of “100 Best Corporate Citizens” by Corporate Responsibility Magazine for the fourth time in a row.
History and Development
Maxwell W. Becton and Fairleigh S. Dickinson met while on a business trip in 1897. Months later, they decided to enter into a professional partnership and sealed it with a handshake. They called their company "Becton, Dickinson and Company". In the same year they sold their first product, a syringe.
In 1898 the first patent for the glass injection syringe based on the Luer system was acquired ; 1899 first company logo; 1904 first own production; 1981 turnover of 1 billion US dollars: 1986 move to the current company headquarters in Franklin Lakes; 1999 new company logo.
In 2014, BD integrated CareFusion and in 2017, CR Bard.
In January 2020, Thomas Poland became BD CEO and President, succeeding Vincent Forlenza.
BD segments
BD is divided into three segments worldwide: BD Medical, BD Life Sciences and BD Interventional.
BD Medical
BD Medical offers an extensive range of medical technologies and devices that are used to improve healthcare in many different areas. This reduces the spread of infections, optimizes the treatment of diabetes, improves drug administration and surgical procedures, and ensures efficient and safe medication management.
Customers in this segment include clinics and hospitals, doctors, government and public health authorities, healthcare workers, pharmacy retailers, pharmaceutical and biotechnology companies, and end users.
BD Life Sciences
BD Life Sciences' product line includes products for the safe collection and transport of diagnostic samples, as well as devices and reagents that can be used to diagnose a wide variety of infectious diseases, nosocomial infections and cancer. The spectrum ranges from the discovery and research of a disease to its diagnosis. The range includes systems for preanalytics for taking, stabilizing and transporting samples, solutions for immunological research, including flow cytometric systems and multiomics methods, as well as for microbiology and molecular diagnostics, laboratory automation and software solutions as well as differentiated reagents and assays.
Customers in this segment are research institutions, industrial and reference laboratories, blood banks, clinics and hospitals, public health institutions, academic and government institutions as well as pharmaceutical and biotechnology companies.
BD Interventional
BD Interventional develops innovative technologies that improve surgical procedures, therapeutic procedures, and patient disease management. The products are used in endovascular interventions, in biopsies, in hernia operations as well as in urology and intensive care medicine. The portfolio is supplemented by products for disinfection.
Customers include clinics and hospitals, doctors, outpatient surgical centers, nurses and end users.
BD in Germany, Austria and Switzerland
BD employs around 2000 people at 12 locations in Germany, Austria and Switzerland.
In 2011, the new building was inaugurated in Heidelberg, which was certified according to the LEED Gold Standard. The so-called green building , which costs 23 million euros, houses laboratories, offices and seminar rooms.
Individual evidence
- ↑ Becton, Dickinson Form 10-K 2017 , accessed November 27, 2017
- ↑ a b BD Annual Report 2019. Accessed June 25, 2020 (English).
- ↑ Fortune 500 Companies: Becton Dickinson. December 1, 2019, accessed June 25, 2020 .
- ↑ Best Corporate Citizens. (PDF) Retrieved June 25, 2020 .
- ↑ a b bd.com: BD History - Highlights from over 115 years of growth , accessed on February 12, 2017
- ↑ Becton Dickinson to buy CareFusion for $ 12 billion in cash, stock (press release). Reuters, October 5, 2014, accessed June 25, 2020 .
- ^ Bard acquisition. In: press release. December 2017, accessed June 25, 2020 .
- ↑ BD Promotes Thomas Poland To CEO And President. In: www.finanznachrichten.de. September 26, 2019, accessed February 4, 2020 .
- ↑ a b c d Becton Dickinson Form 10-K, Annual Report. November 27, 2019, accessed June 25, 2020 .
- ↑ Company information on Kununu. Retrieved June 25, 2020 .
- ↑ Doris Popp: BD inaugurates new customer center in Heidelberg. Vogel Business Media, September 27, 2011, accessed January 14, 2013 .